Levosimendan Eql Pharma (Levosimendan)

Levosimendan binds to troponin C in heart muscle cells, increasing the sensitivity of the contractile proteins to calcium without raising intracellular calcium levels. This results in stronger heart contractions. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous dilation that lowers preload and afterload.

The dosing regimen for Levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, severity of heart failure, and response to therapy. Healthcare professionals set the infusion rate and duration according to established guidelines and individual patient factors.

Safety data for Levosimendan in pregnancy and lactation are limited, and the product is generally not recommended for use unless the potential benefit justifies the potential risk to the fetus or infant. Physicians should evaluate the risk‑benefit profile before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike traditional inotropes that increase intracellular calcium, Levosimendan enhances contractility by sensitizing troponin C to existing calcium, which may reduce the risk of calcium‑overload‑related arrhythmias. Additionally, its vasodilatory action can improve hemodynamics without the same degree of tachycardia seen with some catecholamine inotropes.

Levosimendan should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. The product should remain in its original packaging until use to maintain stability and sterility.

Levosimendan is given as an intravenous infusion. The preparation is typically administered through a controlled infusion pump, allowing precise rate adjustments. Administration is performed by qualified healthcare personnel in a monitored clinical setting.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare cases of sudden cardiac death. Patients should be closely monitored for blood pressure changes, cardiac rhythm disturbances, and signs of ischemia throughout the infusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals receiving other potent vasodilators where additive blood pressure lowering could be dangerous. Caution is also advised in patients with significant hepatic or renal impairment.